

Serial No. 09/994,466; Attorney Docket No. AREX-P03-002

In the specification:

~~Please amend the paragraph beginning on page 1 between lines 4 and 5:~~ IDC-B1,AMD

CROSS-REFERENCE TO RELATED APPLICATIONS

~~This~~ The present application claims the benefit of priority to the following applications:
 U.S. Provisional Application Serial No. 60/270,471 filed February 21, 2001; and U.S.
 Provisional Application Serial No. 60/270,456 filed February 21, 2001; and is a continuation-in-
part of U.S. Serial No. 09/724,094, filed November 28, 2000, now abandoned, which claims
priority to is a continuation of U.S. Serial No. 09/641,833, filed August 18, 2000, now U.S.
Patent 6,716,966, which claims the benefit of U.S. Provisional Application Serial No.
 60/164,714, filed November 11, 1999, and U.S. Provisional Application Serial No. 60/149,492,
 filed August 18, 1999. The entire contents of each of these priority applications is hereby
 incorporated by reference.

page 23 line 7

Please add the following new paragraph after line 23 of page 7:

IIFW sent

A cell line which produces the monoclonal antibody Alt-1 was deposited on November 23, 1999, at the American Tissue Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, and was given the ATCC accession number PTA-975. This deposit will be maintained under the conditions of the Budapest Treaty. All restrictions upon public access to the deposited material will be irrevocably removed upon the grant of a patent of this application.

IDC-B2,AMD